Clinical Trial Update: Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. [Phase 2]

View source ↗

Summary

Phase 2 trial update on the efficacy and safety of ruxolitinib in treating anemic myelofibrosis, with completed status and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Myelofibrosis, Post-Polycythemia Vera-Myelofibrosis | Phase 2 | Status: COMPLETED | Results posted: 2020-04-30